Background & Aims

Cough is a very common symptom causing medical consult. Several remedies are readily available in the market however these are currently not recommended among the pediatric population due to a few reasons which include the benign nature of acute cough, limited effectivity and lack of support from the United States Food and Drug Administration (USFDA) due to abuse potential.

This case report demonstrates the adequacy of Pregabalin as a supportive antitussive medication in a patient with an cough neuropathy secondary to a viral infection.

Methods

n/a

Results

n/a

Conclusions

The introduction of new drugs to the pediatric population is difficult. Careful titration of medication to determine the effective and right dosing is important. Our study has demonstrated the effectiveness of using Pregabalin as a supportive antitussive drug in the treatment of a Filipino child with an acute cough.

References

1.Lam, S. H., Homme, J., Avarello, J., Heins, A., Pauze, D., Mace, S., Dietrich, A., Stoner, M., Chumpitazi, C. E., & Saidinejad, M. (2021). Use of antitussive medications in acute cough in young children. Journal of the American College of Emergency Physicians Open, 2(3). https://doi.org/10.1002/emp2.12467
2.Vogelberg, C., Cuevas Schacht, F., Watling, C. P., Upstone, L., & Seifert, G. (2023). Therapeutic principles and unmet needs in the treatment of cough in pediatric patients: Review and expert survey. BMC Pediatrics, 23(1). https://doi.org/10.1186/s12887-022-03814-0
3.Waring, G., Kirk, S., & Fallon, D. (2019). The impact of chronic non-specific cough on children and their families: A narrative literature review. Journal of Child Health Care, 24(1), 143–160. https://doi.org/10.1177/1367493518814925
4.Bonnes, J., & Meyers, G. (2020). What is the efficacy of OTC antitussives for children with a viral URI? Evidence-Based Practice, 23(4), 20–21. https://doi.org/10.1097/ebp.0000000000000611
5.Cross, A. L. (2022, November 14). Pregabalin. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK470341/
6.Pregabalin. (n.d.). https://www.bionity.com/en/encyclopedia/Pregabalin.html
7.Chan, P. L. S., Marshall, S. F., McFadyen, L., & Liu, J. (2021, July). Pregabalin population pharmacokinetic and exposure-response analyses for focal onset seizures in children (4-16 years) and adults, to support dose recommendations in children. Clinical pharmacology and therapeutics. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359225/
8.Model-informed drug development in pediatric dose selection. (n.d.). https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.1848
9.Al-Biltagi, M., Bediwy, A. S., & Saeed, N. K. (2022). Cough as a neurological sign: What A clinician should know. World Journal of Critical Care Medicine, 11(3), 115–128. https://doi.org/10.5492/wjccm.v11.i3.115
10.Li, J., & Ye, L. (2019). Effect of pregabalin for the treatment of chronic refractory cough. Medicine, 98(23). https://doi.org/10.1097/md.0000000000015916
11.Decoster, L., Van der Goten, A., Eerens, I., Goffin, K., & De Rycke, A. (2019). A rare cause of chronic cough. Thorax, 74(5), 521–522. https://doi.org/10.1136/thoraxjnl-2018-212435

Presenting Author

Rosalee E. Gonzales

Poster Authors

Rosalee Gonzales

MD

St. Luke's Medical Center Quezon City

Lead Author

Topics

  • Models: Chronic Pain - Neuropathic